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The ready availability of inbred  strains,  ability to withstand  microvascular 
surgery, and the ease of production of immunological enhancement have made 
the rat a  popular and valuable model for organ transplantation.  A  number of 
studies in the mouse employing skin allografts have demonstrated the central 
role of gene products of the major histocompatibility H-2 complex in the rejection 
process.  Fragmentary  understanding  of the  rat major histocompatibility  gene 
complex  (MHC) 1 has  limited  the  general  applicability  of  data  obtained  by 
studying  rat  organ  transplantation.  Because  important  differences  exist  be- 
tween  the  immunobiology of skin  and  organ  allografts  (1),  it is important  to 
develop a full understanding of the rat MHC. Recent studies have indicated that 
rat gene products identical to or closely linked to the serologically defined Ag-B 
system  function  as  immune  response  genes  (2,  3)  and  stimulate  the  mixed 
lymphocyte culture  response (4).  These studies suggest,  therefore, that the rat 
MHC  bears close  similarity  to the  more extensively mapped MHC  regions  of 
primates and the mouse. 
The phenomenon of passive enhancement of tumor and tissue allografts (1, 5) has been 
shown to be associated with only minimal alteration in cellular immune responsiveness 
in the host (6). In contrast,  immunopathological (7,  8) and humoral studies (6-9) have 
emphasized the depression of host humoral responsiveness and suggest an impairment of 
B-T-cell cooperation (6). Still, the mechanism by which passive immunization produces 
this deviation in the immune response remains speculative. An important recent advance 
has been the finding that, while antibodies of different classes (10) and physicochemical 
characteristics (11) can induce enhanced graft survival, antibodies specific for the prod- 
ucts of the K and D regions of the mouse MHC are unnecessary (12). Similarly, in the rat, 
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heart allografts appear equally well enhanced by an alloantiserum whether it has been 
absorbed with Ag-B antigen-bearing donor red blood cells (RBC) or not (13). Such studies, 
while not eliminating the possible importance of spontaneously reversed rejection epi- 
sodes (14), strongly suggest that antigens other than the products of the K and D  regions 
of the mouse MHC and of analogous %erologically-defined" Ag-B antigens in the rat are 
of prime importance in passive enhancement. 
The present study shows that a rat alloantiserum, which has been extensively 
absorbed with donor strain RBC or platelets,  is as effective as the unabsorbed 
antiserum in inducing renal graft enhancement.  Furthermore,  absorbed anti- 
sera inhibit the mixed lymphocyte culture and specifically block donor lympho- 
cyte Fc receptors.  We suggest that the specificities of antibodies of predominant 
importance  in  passive  enhancement  in  rat  allotransplantation  are  directed 
against antigens analogous to those coded for by the Ir region of the mouse MHC 
(15), since the I region antigens (Ia) and Fc receptors seem to be closely related 
(16).  An hypothesis  unifying our present  knowledge  of the  rat  MHC  and the 
immunologic alterations observed during the induction of enhancement is pre- 
sented. 
Materials  and Methods 
Animals.  Inbred rats,  weighing  ~200  g,  Buffalo  (BF)  Ag-B  ~,  Brown-Norway  (BN)  Ag-B  3, 
Lewis (Lew) Ag-B  I, Wistar Furth (WF) Ag-B  4,  and ACI Ag-B  ~  were purchased from Microbiologi- 
cal Associates, Bethesda,  Md., as were the following F, hybrids: (Lew/BN)F,, (Lew/BF)F, and 
(Lew/ACI)F,. August (AUG) rats,  Ag-B  '~,  were kindly provided by S. M. Poiley,  National Cancer 
Institute,  Bethesda, Md. F2 hybrids from (Lew/BN)F, × (Lew/BN)F, matings and either  homozy- 
gous at the Ag-B locus  [(Lew/Lew), (BN/BN)] or heterozygous (Lew/BN) were kindly provided by 
Dr. R. M. Williams, Harvard Medical School, Boston, Mass. AKR  male mice, deficient  in C5 
complement, were purchased from The Jackson Laboratory, Bar Harbor, Maine. 
Kidney Transplantation.  Rat renal allografts were performed after bilateral nephrectomy of 
the recipients, as previously described (6,  17). Animals in experimental groups received intrave- 
nous injections of a  particular hyperimmune  serum  (HIS),  Lewis  anti-BN,  immediately  after 
transplantation, whereas control rats received no therapy. Blood urea nitrogen (BUN) levels were 
measured weekly in each animal. Rats dying within the 1st wk after surgery were autopsied and 
removed from the study if an obvious technical failure had occurred. 
Hyperimmune Allogeneic Sera (HIS).  Lew rats were immunized with a  single BN skin graft 
followed by biweekly injections for 2 mo of pooled BN lymphocytes (107-108) harvested from spleen, 
bone marrow,  and lymph  node.  Animals were  bled by  aortic puncture  10  days  after the  last 
injection, and the sera were pooled and heat inactivated for 30 min at 56°C.  Two pools (no. 23 and 
26) with the same lymphocytotoxicity and hemagglutinating titers were used. 
RBC-Absorbed Sera (RAS).  Heparinized BN blood was washed two times with saline and the 
buffy coat removed. The remaining cells were filtered through a packed cotton column, and after 
centrifugation the top fourth of packed RBC were discarded. The remaining RBC were layered 
onto a  Ficoll-Hypaque  density gradient (sp  gr  1.094)  and centrifuged at 300 g  for  15 rain.  The 
sedimented RBC were washed twice in normal saline and checked for purity by acridine orange 
staining. HIS was then absorbed with these BN RBC by mixing 1 vol of HIS with 2 vol of RBC for 4 
h  at 37°C,  followed by a  12 h  incubation at 4°C with constant stirring. This absorption procedure 
was repeated three times. 
Platelet-Absorbed Sera  (PAS).  Citrated  BN blood was diluted with normal saline (1:4) and 
centrifuged at 200 g  for 10 rain. The supernate was aspirated and centrifuged twice at 200 g  before 
pelleting the platelets at 1,000 g  for 20 min. The absence of leukocytes was confirmed by acridine 
orange staining.  Repeated  absorptions of HIS  were performed as above,  utilizing the platelets 
from 40-50 ml of BN blood for absorption of 1 ml of HIS. The absorptions were performed at 37°C 
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Thymus-  and  Splenocyte-Absorbed  Sera  (TAS-SAS).  HIS  was  absorbed  three  times  with 
either 1.2 ×  10  ~ per ml of Ficoll-Hypaque purified splenocytes or thymocytes. Incubations were at 
37°C for 4 h, followed by a  4-h period at 4°C with constant agitation. All the absorbed sera were 
then diluted (1:3) with RPMI  1640 medium and sterilized by micropore filtration (HAWP 02500; 
0.45 Millipore Filter Corp., Bedford, Mass.). Samples of sera were stored at -20°C. 
Acridine  Orange  Staining.  Five  drops  of  saline  saturated  acridine  orange  dye  (National 
Analine) were added to 10 ml of 95% ethylalcohol. The diluted dye was poured over clean slides and 
dried (18). One small drop of a cell preparation was plated on the stained slide and examined under 
a cover slip with blue illumination (Zeiss microscope, #B050 mercury lamp, K490 excitor, and 510 
suppression filters; Carl Zeiss, Inc. New York). 
Preparation of  F(Ab')~.  Pure IgG was prepared from 10 ml of HIS and PAS previously dialyzed 
for 2 h  against 0.05 M Tris buffer (pH 7.6)  and placed upon a  50-ml column of DEAE 52 cellulose 
(Whatman Lab.,  England) in the same buffer. The eluted IgG was immunochemically pure,  as 
assessed by immunoelectrophoresis with rabbit antirat serum (Cappel Lab.,  Downington,  Pa.). 
The IgG was then digested with pepsin (2,560 U/mg, Sigma Chemical Co.,  St. Louis,  Mo.) at an 
enzyme/substrate ratio of 1:40 in acetate (0.075 M) saline (0.005 M) buffer (pH 4.5) for 18 h at 37°C. 
An equal  amount  of pepsin  was  added before  an  additional 4-h incubation; the reaction  was 
stopped by raising the pH to 8 with solid Tris. Immunoelectrophoretic analysis revealed a  triple 
pattern characteristic of a  mixture of F(Ab')2 and nondigested IgG. After dialysis against phos- 
phate-buffered saline (pH 7.6)  at 4°C,  the preparation was applied to a  100 cm  ×  1.5 cm G-200 
Sephadex column. Three peaks were obtained: undigested IgG (19.5%), F(Ab')~ (49%), and a small 
diffuse peak of a lower molecular weight which contained the Fc fragments (30.7%). The first and 
second peaks gave single but not identical bands upon immunoelectrophoretic analysis against 
rabbit anti-IgG and were, respectively, the undigested IgG fraction and F(Ab')2 fraction. Rabbit 
antirat IgG F(Ab')2 was prepared in the same manner, but an enzyme/substrate ratio of 1:100 and 
a single 18-h digestion was employed. The F(Ab')2 preparations were adjusted to a concentration of 
5 mg/ml. 
Antibody  Elution  from  Platelets.  The  pooled  pellet  of  platelets  used  for  absorption  was 
incubated in a  citrate buffer (pH 3.2) at 37°C for 2 h  with constant agitation. The mixture was 
centrifuged at high speed, and the supernate was collected and immediately buffered to pH 7.2. A 
second elution was performed on the same platelet pellet. 
Assessment of the Sera.  Each antiserum was tested for complement-dependent cytotoxicity 
titer against 5~Cr-labeled splenocytes, as previously described (19), and for hemagglutination titer 
using BN RBC in a microcapillary method (20). F(Ab')2 fragments were devoid ofcytotoxicity, but 
were  shown  to  inhibit the  complement-dependent  cytotoxicity  assay:  5~Cr-labeled  spleen  BN 
splenocytes were preincubated for 40 min at room temperature with HIS F(Ab')2, washed, and the 
cytotoxicity assay was performed using these preincubated target cells.  HIS F(Ab')2 fragments 
retained the hemagglutination titer of undigested HIS. 
Mixed  Lymphocyte  Culture  (MLC).  MLC  was  performed  with  2-mercaptoethanol  (2-ME) 
(Sigma  Chemical  Co.)  supplemented  media,  as  previously  reported  (19).  Briefly,  cells  were 
harvested under sterile conditions from spleen after exsanguination of the animals.  0.75  ×  106 
responding cells were mixed with an equal number of mitomycin C-treated stimulating cells, in 
microtiter plates (Cooke  Laboratory  Products,  Alexandria,  Va.) (flat bottom  18-29A).  The test 
sera were added to the MLC in various dilutions and a~usted to a  10% final serum concentration 
with normal Lew rat sera. 
EA Rosette Assay.  Sheep red blood cells (SRBC) (Baltimore Biological Laboratories,  Balti- 
more, Md.) less than 1-wk old, were washed three times, adjusted to 1%, and mixed with an equal 
volume of various dilutions of the IgG-enriched fraction (Sephadex G-200) of rabbit anti-SRBC 
immune  serum  (Baltimore  Biological).  A  1/3,000  dilution of IgG  was  adopted  as  the  optimal 
sensitizing dose.  After 1 h  at 37°C followed by 1 h  at 4°C the cells were washed twice,  and the 
indicator cells were stored for up to 4 wk without loss of activity. Rosettes were formed by mixing 
0.5  ×  l0  s lymphocytes in 50/~l of RPMI 1640 with 50 ~1 of 1% sensitized SRBC and 25 ~1 of SRBC 
absorbed fetal calf serum (FCS) (Grand Island Biologicals, Grand Island, N. Y.) and centrifuging 
at 200 g. After 45 min incubation at 37°C the cells were gently resuspended and a drop placed on an 
acridine orange-stained microscope  slide for examination.  The number of rosettes were  deter- 
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enumerated. This method permits definition of the nuclear morphology of the cells; only mononu- 
clear ce|ls were counted. A rosette was defined as three or more RBC bound to a mononuclear cell. 
In rosette inhibition experiments, the lympyhocytes were preincubated with various dilutions 
of the test sera for 45  rain at room temperature and then washed once before using for rosette 
formation. 
EAC Rosettes.  The first peak of the G-200 elution of  rabbit anti-SRBC serum, enriched in IgM, 
was added at a  1:2,000  dilution to 2%  SRBC, incubated for 30 min at 37°C and 30  rain at 4°C, 
washed twice, and incubated for 30 rain at 37°C with a  1:5 dilution of C5-deficient AKR mouse 
serum.  The rabbit antisheep (IgM) plus complement-coated SRBC  (EAC)  were washed twice, 
resuspended to 1% in a  mixture of equal parts of RPMI 1640 and isotonic EDTA (0.04  M),  and 
stored for up to 4 wk at 4°C. EAC rosettes were formed by mixing 0.5  × 106 |ymphocytes  in 0.8 ml of 
RPMI/EDTA solution with 0.2 ml of 1% EAC, incubating for 15 min at 37°C, and centrifuging at 
200 g  for 5 min with immediate resuspension. Experiments performed with IgM-sensitized RBC 
(but not incubated with AKR mouse serum) did not result in the formation of rosettes. Rosette 
inhibition experiments were performed as described for rabbit antisheep (IgG)-coated SRBC (EA) 
rosettes. 
Results 
In Vivo Study 
DOSE  DEPENDENCE  OF HIS ENHANCING  EFFECT.  The enhancing effect of HIS 
upon rat renal allografts has been described in detail by our laboratory (6, 7). 1/2 
ml of HIS was able to prolong indefinitely the survival of (Lew/BN)F1  kidneys 
transplanted into a  LeT host (Fig.  1).  The  LeT recipients exhibited slightly 
increased BUN  levels at the end of the 2nd wk after transplantation with a 
subsequent decline to approximately normal values. All the animals receiving 
0.5  ml  of HIS  became  long-term survivors.  Rats  receiving 0.3  ml  showed  a 
marked increase in BUN (155-  + 70 mg/100 ml) and two of six recipients died 2 wk 
postgrafting.  The  remaining four rats  recovered from rejection episodes and 
became  long-term  survivors  with  renal  function similar  to  that  of animals 
receiving 0.5 ml of HIS. Three of six rats receiving 0.1 ml of HIS died, and all 
exhibited a marked increase in the BUN (220 + 110 mg/100 ml). Interestingly, the 
three  animals  surviving the  3rd  wk  recovered  excellent renal  function and 
became long-term survivors. The control transplanted group consisted of nine 
rats that did not receive any serum. All of these animals exhibited a major and 
early rise in the BUN level, and eight died within the first 20 days after surgery, 
while one recovered and became a  long-term survivor. It is evident that HIS 
protected (Lew/BN)FI transplants in Lew recipients, and that this enhancing 
effect is  dose  dependent  as  assessed  by  the  mortality rate  and  severity of 
rejection crises. 
STRAIN  SPECIFICITY OF THE  ENHANCING  HIS ACTIVITY.  Previously published 
experiments on the specificity of enhancement using different enhancing models 
are  in conflict (14, 21). We tested the  ability of the anti-BN  HIS to  protect 
semiallogeneic  kidneys  transplanted  into  LeT  recipients  (Table  I).  When 
(BF/Lew)F~  and (ACI/Lew)F~ kidneys were transplanted into Lew hosts all the 
recipients died within 2 wk except for one animal which spontaneously became a 
long-term survivor. The group injected with 0.5 ml of Lewis anti-BN HIS, which 
was able to enhance 100% of (Lew/BN)F1 donor kidneys, as shown above, was 
ineffective with (BF/Lew)FI or (ACI/Lew)F, kidneys as shown in Table I. One 
treated (BF/Lew)F, graft became a long-term survivor as in the control group. 
These results show that, in the three inbred strains tested, the ability of the SOULILLOU,  CARPENTER,  d'APICE,  AND  STROM  409 
300-  /  14  o  0.5 ml 
9  •  013  ml 
/i~  •  0.1 ml  ~"~,~  a  No Serum 
-~  200  o 
o 
I  E 
z  /  /  4  2 
,~n 100  f 
-,-  j 
1  2  3  4  5  6  7 
WEEKS 
FIa.  1.  Dose  response  effect  of  HIS  in  rat  renal  allografts.  Lew  rat  recipients  of 
(Lew/BN)F~  grafts receiving 0.5 ml (O), 0.3 ml (Q), 0.1 ml (b), or no HIS (D).  The number 
adjacent to the mean -+ SD of  BUN represents the number of  surviving rats in each group at 
each time period. 
HIS to enhance semiallogeneic grafts is restricted to grafts expressing the BN 
MHC haplotype. 
EHANCING  EFFECT  OF THE  ABSORBED  SERA.  Three successive absorptions of 
HIS  with  BN  RBCs  resulted  in  maximal  removal of cytotoxic antibodies;  a 
fourth absorption did not remove additional cytotoxicity. The 18% specific lysis 
produced  at  the  1:6  dilution  of the  RAS  plateaued  over  the  next  two  log2 
dilutions and then declined sharply (Fig. 2). RAS was almost completely devoid 
of anti-BN hemagglutinating  activity, while unabsorbed HIS had an end point 
titer of 1/1,728.  Calculations from the hemagglutination  titer showed that less 
than 0.7% of the hemagglutinating  antibody activity remained after the absorp- 
tion.  Five Lew rats receiving (Lew/BN)F, kidneys and injected with 0.5 ml of 
RAS all became long-term survivors.  Moreover, the mean posttransplant  BUN 
levels were equal to those in the group enhanced with nonabsorbed HIS (Fig. 3). 
PAS exhibited lower cytotoxicity against 51Cr_labeled  BN splenocytes than did 
RAS,  but  with  the  same  plateau  over the  early  serial  dilutions  (Fig  2).  No 
hemagglutinating  activity was detected after platelet absorption. The PAS also 
produced  a  good  enhancing  effect as  shown  by the  survival  rate  and  renal 
function of this group of grafted rats (Fig.  3). 
TAS and  SAS completely depleted  of both cytotoxic and  hemagglutinating 
activity were unable to protect (Lew/BN)F~ transplanted kidneys; all five rats in 
each group died within 2 wk (Fig.  3). 
We conclude that  RAS and PAS are  able to produce enhancement  of renal 
allografts  at  doses  comparable  to  those  of the  unabsorbed  HIS.  Anti-Ag-B 
antibodies,  as defined by classical serological techniques,  remaining  after ab- 
sorption could not be quantitatively sufficient to explain this effect as shown by 
the HIS dose response studies (Fig.  1). Therefore, in vitro studies of HIS and its 410  FC  RECEPTORS  IN  ENHANCEMENT 
TABLE  I 
Specificity Control of LEW Anti-BN Antiserum 
Combination 
donor -* host 
BUN perweek 
1  2  3  4  5 
Survival 
days 
(LEW/BN)F, --* LEW 
Control * 
Enhanced$ 
(LEW/BF)F,-*LEW 
Control* 
Treated$ 
(LEW/ACI)F, --* LEW 
Control* 
Treated$ 
245 
22O 
330 
28O 
440 
120 
290 
300 
280 
340 
420 
370 
410 
275 
280 
285 
270 
350 
280 
250 
w 
330 
380 
38O 
mg/lO0 ml 
55  90  175  140  140 
70  70  65  40  45 
25  190  I00  65  65 
25  70  90  70  90 
60  80  60  105  70 
40  75  90  80  60 
55  55  60  50 
65  190  120  110 
7 
7 
8 
7 
16 
10 
>35§ 
>35§ 
>35§ 
>90 
>35§ 
>90 
23 
i0 
>90 
9 
8 
11 
8 
12 
44 
7 
9 
8 
8 
12 
11 
*  Transplanted animals without injection  of  serum. 
Animals receiving 0.5 ml of  LEW  Anti-BN HIS at the time of  transplantation. 
§  Animals used for  other experiments 5 wk after  successful  transplantation. SOULILLOU,  CARPENTER,  d'APICE,  AND  STROM  411 
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FIG.  2.  Lymphocytotoxicity titer of various absorbed sera. The results are expressed as 
percent target specific lysis according to the formula: (Ex -  SR)/(Ft -  SR) × 100, where Ft is 
the mean counts per minute (cpm) obtained from supernates after freezing and thawing 
aliquots of slCr spleen target cells. Spontaneous release (SR) is the mean cpm obtained from 
the supernate of target cells incubated either with test anti-sera or complement alone. Ex is 
the mean cpm obtained after incubation of target cells with the test sera and complement. 
HIS is Lew anti-BN. Absorption with BN spleen (SAS) removes all  activity, while some 
degree of cytotoxicity against spleen is retained after exhaustive absorption with RBC 
(RAS) or platelets (PAS). 
absorbed  derivatives  were  performed  in  an  attempt  to  define  the  antigen(s) 
recognized by PAS and RAS. 
In Vitro Studies 
EFFECT OF THE SERA ON MLC.  When HIS was added to Lew plus BN~ MLC, 
the  [3H]thymidine  uptake  was strongly  inhibited.  A  normal  proliferative  re- 
sponse occurred only with dilutions of HIS equal to or greater than 1:1,200 (Fig. 
4). The HIS also blocked the reciprocal BN plus Lewm MLC. The specificity of the 
HIS inhibitory effect upon MLCs was studied by using Lew responder cells with 
stimulator  cells harvested from four other inbred strains  (BF,  WF,  ACI,  and 
AUG) differing  at the major histocompatibility locus (Ag-B).  High concentra- 
tions  of HIS inhibited  each of these  MLC  combinations  (Fig.  4  a).  However, 
higher dilutions of HIS (1:640)  inhibited (approximately 60%) only the specific 
Lew plus BNm combination (Fig. 4 a), and none of the other four combinations 
were blocked at these dilutions.  HIS tested at high concentrations (1:10) in the 
reciprocal  MLC  combinations,  i.e.  Lewm as stimulator  cells,  diminished  only 
slightly the [3H]thymidine incorporation of the WF, ACI, and AUG responders, 412 
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FIG. 3.  Enhancing ability of absorbed HIS. The symbols represent the mean _+ SD of the 
BUN level of Lew rats transplanted with a (Lew/BN)F~ kidney. Spleen- and thymus-ab- 
sorbed sere were ineffective,  while platelet or RBC absorbed sere were comparable to the 
Lew anti-BN HIS. V2-ml doses were given in each case. 
but,  as previously noted,  abolished the response of BN responders (Fig.  4 c). 
MLCs performed in the presence of PAS also inhibited all MLC combinations 
with Lew responder cells; however, higher concentrations of PAS than HIS were 
required for inhibition (Fig.  4 b). The specific inhibitory effect of PAS at high 
dilutions on BNm  ×  Lew combinations was less pronounced than with the HIS. 
TAS and SAS were unable to block the MLC even at a 10% concentration (Fig. 4 
b). Sephadex G-200 fractions of HIS, RAS, and PAS (with fractions of Lew NRS 
as controls) were tested in MLCs and demonstrated that blocking activity was 
confined  to  the  IgM  and  IgG-enriched fractions,  suggesting  that  the  active 
component is an antibody.  Thus,  HIS blocked MLCs between Lew responder 
cells  and  BFm,  WFm,  ACIm,  and  AUGm  cells,  indicating  shared  specificity 
between these strains. However, at high dilutions (up to 1:640) HIS was able to 
discriminate the specific immunizing BN strain. In the reciprocal MLC (Lewm), 
high concentrations of HIS specificity blocked the BN plus Lew~ combination. 
Absorption with BN thymocytes or spleen cells, but not platelets, removed the 
inhibitory effect on the MLC. 
EFFECT OF  THE  SERA  ON  FC  AND  COMPLEMENT  RECEPTORS.  When Lew, WF, 
BF, ACI, AUG, or BN spleen lymphocytes were preincubated for 45 min in 10% 
HIS or normal Lew sera before the EA rosetting procedure, HIS abolished the 
capacity of BN cells, but not those of  other strains, to rosette with EA (Table II). 
RAS and PAS were also strongly inhibitory to BN EA rosettes. Rabbit antirat 
IgG  inhibited  EA  rosette  formation,  but  this  effect was  not  strain  specific. 
Blocking of FITC-IgG aggregate binding (16) was  also  produced by  HIS  and 
PAS. SAS was devoid of any blocking activity. Antibodies eluted from platelets SOULILLOU,  CARPENTER,  d'APICE,  AND  STROM  413  ~B~  @  wFo 
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Fro.  4.  Effect of HIS,  PAS, TAS, and SAS on the MLC.  (a)  Lew lymphocytes are the 
responding cells of a one-way MLC performed with various rat strains in the presence of 
various concentrations of HIS. (Log2 dilution of 1 is 10% HIS). Each point represents the 
mean values obtained when Lew cells were mixed with mitomycin-treated cells (BNm, WFm, 
AUGm, ACIm) in the presence of HIS. (b) Same as (a), but MLCs were performed in the 
presence of absorbed sera as indicated. (c) Here Lewm lymphocytes are used as stimulating 
cells and mixed with the other allogeneic cells as responders in the presence of 10% HIS, 
shown by the right hand speckled bar, or in 10% normal rat serum on the left. Only the BN 
× Lewm combination is inhibited. 
(used  for  anti-Ag-B  absorption),  having  a  hemagglutinating  titer  of  1:1,920, 
were unable  to block rosette formation,  evidence that  the membrane  antigens 
blocked by the absorbed sera are not classical Ag-B. 
To rule out the possibility that  antigen-antibody  complexes were causing the 
specific blocking phenomenon,  additional control experiments  were performed. 
Supernates  collected after the incubation of HIS with BN lymphocytes failed to 
inhibit EA rosettes formed by Lew and BN cells. Furthermore,  when  WF, BF, 
ACI,  or  Lew  cells were  mixed  with  an  equal  number  of BN  cells during  the 
preincubation step with HIS, inhibition of the rosette score averaged 58% (Table 
III), indicating that the inhibitory effect of HIS upon EA rosettes is restricted to 
cells expressing the BN genotype. Furthermore,  F(Ab')2 obtained from PAS was 414  FC  RECEPTORS  IN  ENHANCEMENT 
TABLE  II 
Effect of Various Sera on EA and EAC Rosettes 
EArosettes  EAC rosettes 
BN  LEW  WF  ACI  AUG  BF  BN  LEW  BF 
% 
NRS  19  22  13  13  14  11.5 
HIS  0  23  12  12  10  11 
RAS  4  19  14  11 
PAS  2  24  11  12 
F(ab')2*  3  17  19 
RaIgG$  0  0  1  0.5 
Platelet eluate  19 
% 
27  20  18 
26  21  16 
* F(ab')2 fraction prepared from PAS (Control LEW 17%, BF 20%). 
$ Rabbit anti-rat IgG (same results were found using F(ab')2 from RaIgG). 
TABLE  III 
Effect of HIS on BN Cells Mixed with Nonrelated Cells 
NRS  HIS  NRS  HIS  NRS  HIS  NRS  HIS 
16  14  WF 
BUF 
ACI 
LEW 
BN 
BN  +  WF 
BN  +  BUF 
BN  +  ACI 
BN  +  LEW 
13  13 
18  0  25  2 
20  6 
15  5 
18  21 
11  12 
18  0  12  1 
17  7 
13  8 
NRS, Preincubation with normal LEW serum. 
HIS, Preincubation with LEW anti-BN HIS serum. 
able to inhibit EA rosettes with BN cells, but not with Lew and BF lymphocytes 
(Table II). These experiments indicate that the specific rosette inhibitory effect 
of the sera is not due to formation of free antigen-antibody complexes but is due 
to the binding of an antibody either to the Fc receptor itself or to a  structure 
spatially closely related on the cell surface. The fact that F(Ab')2 fragments are 
inhibitory indicate that inhibition is caused directly by antibody binding and not 
as a  secondary result  of binding  with subsequent Fc site  interaction  with Fc 
receptors. 
Further  study of the  genetic segregation  of the  HIS "anti-Fc"  activity was 
performed in F, and F~ generations of Lew and BN parental strains. The degree 
of inhibition of EA rosette formation by the (Lew/BN) F, cells (compared to BN 
cells)  was  assessed  after  preincubation  with  various  dilutions  of HIS.  High 
concentrations (1:10) of the HIS inhibited BN rosettes by 85% compared to 44% 
for the (Lew/BN)F, cells (Fig.  5). At higher dilutions the discriminatory effect 
persisted: a 1:1,000 dilution did not affect (Lew/BN)F, EA rosetting capacity, but t-- 
<~ 
u~ 
z 
O 
b-- 
T 
z 
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SO 
40 
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Fla. 5.  Inhibition of EA  rosette formation  of (Lew/BN)F~  and BN  lymphocytes  after 
preincubation with HIS. The degree of  inhibition  is  greatest  with BN (C) cells  compared to 
(Lew/BN)F~ (O) cells  at all  dilutions  of  HIS. Individual experiments are shown along with 
the means +-- SD for each group. 
TABLE  IV 
Inhibition of EA Rosettes in F~ LEW  × BN Litter Mate after 
Preincubation with LEW Anti-BN HIS 
HIS  LEW/LEW*  LEW/BN*  BN/BN* 
1:10  15~  75  85 
1:100  4  25  28 
1:1,000  0  0  39 
* Rats typed by cytotoxicity  assay and MLC. 
Result expressed as percent of  inhibition;  control  values are obtained 
after  incubation with normal LEW  serum. 
reduced BN rosette formation by 24%. Typing of (Lew/Lew)F2, (Lew/BN)F~ and 
(BN/BN)F2 rats showed an absence of EA blocking activity in the homozygote 
(Lew/Lew), while a strong inhibition was found in the BN/BN homozygote. The 
heterozygote (Lew/BN) showed a lesser degree of blocking. Data from one of two 
experiments performed with F2 animals are shown in Table IV. 
In contrast to its effects on EA rosette formation, HIS was completely ineffec- 
tive in blocking EAC rosette formation by cells of the three strains tested, using 
the same preincubation procedure used for EA rosette inhibition (Table III). 
Discussion 
This  study demonstrates  that  HIS Lew anti-BN  antibodies specifically en- 
hance renal grafts expressing the BN genotype. The administration of 0.5 ml of 
hyperimmune Lewis anti-BN alloantiserum  (HIS) at the time of kidney trans- 
plantation greatly reduced the initial rejection crisis and insured the survival of 
all (Lew/BN)F1 kidneys in Lew hosts; however, 0.1 ml enhanced only half the 
animals,  and all such survivors exhibited a strong initial rejection episode (Fig. 416  FC  RECEPTORS  IN  ENHANCEMENT 
1). (BF/Lew)F1 or (ACI/Lew)F, kidneys transplanted in Lew hosts were not at all 
enhanced  by  Lewis  anti-BN  sera.  The  immunological  specificity discerned 
for the MHC is in agreement with studies performed in the mouse tumor model 
(21). 
When  Lewis  anti-BN  HIS  was  absorbed  with  BN  platelets  or  RBC,  the 
enhancing properties persisted, even though little or no anti-Ag-B activity, as 
assessed by lymphocytotoxicity  and hemagglutination, was present. These data 
clearly indicate that no correlation exists between the presence of classical anti- 
Ag-B antibodies and the passive enhancement properties of HIS, as previously 
thought by some  authors  (22), and  is  in agreement with other observations 
showing no correlation between anti-Ag-B titers and enhancing potency (23). 
The antibodies remaining in the PAS and RAS are directed to antigens present 
on lympocytes, but not on platelets or RBC. Such sera are similar with regard to 
low cytotoxicity levels to anti-Ia sera described in the mouse (24). These/-region 
specificities are not represented on the RBC and platelet membranes and are 
preferentially expressed on B cells. Unpublished experiments performed in this 
laboratory demonstrate that rat platelets are unable to stimulate a proliferative 
response when mixed with allogeneic lymphocytes, over a wide range of plate- 
let/lymphocyte ratios, and over a prolonged time-course, suggesting also a lack 
of MLR determinants on rat platelet membranes.  However, in the absence of 
congenic strains in the rat one can only suggest a strict analogy with the mouse. 
Although traces of anti-Ag-B may remain after absorption, this is an unlikely 
explanation for the enhancing activity, since a  dose of HIS of one-fifth of the 
normal dose injected no longer enhanced grafts, while the RAS containing less 
than 1% of the total amount of  the hemagglutinating activity originally present 
was  fully effective.  These  in  vivo  observations  are  in  agreement  with  the 
experiments performed in the rat heart allograft model (13) in which donor RBC- 
absorbed August (Ag-B 1) anti-Wag (Ag-B 2) serum was as effective as unabsorbed 
serum in promoting long-term cardiac allograft survival.  Our data show not 
only that the transplant recipients become long-term survivors, but also that the 
early rejection episode is abrogated, additional evidence that enhancing activity 
is fully retained in the RAS (Fig. 1 and 3). 
Two other possible explanations for the enhancing effect of absorbed HIS must 
be excluded before the conclusions drawn regarding anti-/region specificities 
can be  considered tenable.  Firstly, is  the  possible  effect of antigen-antibody 
complexes formed during the  absorption  procedure  with platelets and  RBC. 
Thymus and spleen absorbed sera should also contain such complexes, but they 
do not enhance allografts. Furthermore, PAS and RAS do not block the forma- 
tion of EA rosettes by lymphocytes that do not express the BN haplotype, a 
phenomenon which would be highly likely if immune complexes were present. 
Davies and Alkins (13) analyzed the IgG peak of an erythrocyte-absorbed serum 
(DEAE purified 12~I-IgG) by filtration through a  Sephadex G-200 column and 
found no difference between the location of the IgG peak immunoprecipitated by 
an antirat IgG serum and that detected by isotopic markers, strong evidence 
against complex formation. Secondly, the PAS and RAS could contain antirecep- 
tor antibodies, Lewis anti(Lew anti-BN), which have been detected in some HIS 
that produce enhancement (25). Such anti-idiotypic antibodies have been re- SOULILLOU,  CARPENTER,  d'APICE,  AND  STROM  417 
ported in sera obtained after hyperimmunization procedures (26); however, the 
HIS we have used lack such a factor (6). 
When tested in vitro, the PAS as well as HIS blocked proliferation in MLC. 
Combinations of BN plus Lewm and Lew plus BNm are both blocked by the HIS, 
findings in agreement with results in humans (27), showing that alloantisera 
block  either  the  responding  or  stimulating cells  as  long  as  the  serum  has 
specificity to alloantigens on one of the cell populations. When Lew cells were 
responding,  strict  specificity to  BN  alloantigens was  discerned  only at  low 
concentrations of HIS or PAS (Fig. 4 a).  High concentrations of HIS inhibited 
the MLC's with "unrelated" Ag-B haplotypes. However, with Lew as stimulator 
cells (Lewm) HIS blocked only the MLC with BN-responding cells (Fig.  4  c). 
Therefore, the phenomenon of '~nonspecific" MLC blocking at high serum concen- 
trations involved only the stimulator cells, indicating that the cross-reactivity is 
directed to a  target cell antigen different from the MLR recognition structure 
present on responding cells.  For example, Lew antibodies on ACI cells which 
block Lew recognition of ACI do not prevent the ACI response to Lew. MLR-S 
antigens have recently been shown to be linked to the MHC (Ag-B complex) in 
the rat (4). They are therefore analogous to/-region specificities (Ia) which in the 
mouse are often defined as public antigens (15) and which appear to be targets 
for the anti-/-region antisera which block the MLC (28). In present studies the 
lack of strict strain specificity in vitro of  the Lew anti-BN HIS is in contrast with 
the  specific BN  genotype specificity of in  vivo  enhancement. The  biological 
relevance, therefore, of the in vitro MLC blocking at high serum concentrations 
is unclear. The problem may be quantitative in that very much larger doses of 
Lew anti-BN HIS might be able to enhance donor grafts of a different genotype; 
alternatively, it is likely that the cross-reacting antibodies are not directed to 
the critical/-region coded recognition-response membrane region. 
Various antisera, including heterologous anti-IgG and anti-B cell sera and 
anti-Ly4.2, have been reported to block mouse lymphocyte Fc receptors  (29). 
Particularly relevant, however, was the demonstration by Dickler and Sachs 
(16) that an anti-Ia serum raised in congenic mouse lines specifically blocked 
lymphocyte Fc receptor binding of IgG aggregates, while antibodies directed 
against the antigenic products of the K and D ends of the MHC were ineffective. 
This  suggests  that  anti-Ia  serum  contains  an  antibody  specific  for  the  Fc 
receptor (and hence the Fc receptor is itself an Ia antigen) or alternatively that 
the Fc receptor and Ia are closely associated on the lymphocyte surface. In the 
present study, this phenomenon was investigated in the rat using EA rosette 
formation as an index of Fc receptor function. The results are strikingly similar 
to those in the mouse. PAS and RAS have properties very similar to mouse anti- 
Ia sera as they are poorly cytotoxic and show immunologic specificity in their 
capacity to block the Fc receptor.  Nonspecific blockade of Fc receptors did not 
occur,  as  shown by controls using the  F(Ab')2  fragments of PAS  (Table  II). 
Moreover, the absence of Fc receptor blocking by the eluate from platelets used 
to absorb HIS shows that Ag-B antigens are analogous in this regard to the gene 
products of the K  and D series in the mouse. However, lack of knowledge of the 
exact location of the I region in the rat (2, 3) and lack of congenic strains makes 
closer comparison unreasonable. The antigen recognized by the anti- ~Tc-recep- 418  FC  RECEPTORS  IN  ENHANCEMENT 
tor" antibody in these experiments appears to be genetically linked to the major 
Ag-B specificities detected by lymphocytotoxicity, as shown by strain specificity 
and its segregation with Ag-B in F2 generations (Table IV). The possibility of 
serotyping for major locus linked/-region specificities by EA rosette inhibition is 
suggested by these results. 
The ability of homozygous BN/BN cells to form EA rosettes was more com- 
pletely inhibited by HIS than was that of heterozygous F, (Lew/BN) cells. This 
finding, of practical importance in interpreting results obtained with cells of 
various haplotype combinations, could be due to decreased efficiency  of antibody 
binding when antigen density is reduced or to a degree of heterogeneity of gene 
expression among individual F~ cells. These findings differ from those obtained 
in the mouse, using the technique of inhibition of aggregated IgG binding by 
anti-Ia antisera (16), in which maximal inhibition occurred with both parental 
and F~ cells. 
Our  results,  taken  as  a  whole,  indicate  that  alloantibodies  inhibiting  Fc 
receptor binding are directed against MHC-linked determinants different from 
the classical "serologically-defined"  Ag-B antigens. Since antibodies to the latter 
are not required for enhancement, our studies parallel those in which antibodies 
raised by immunizing mice differing only by the I  and K  regions of the MHC, 
and absorbed with RBC, have been reported to enhance mouse skin grafts (12). 
In addition,  it  has  been reported (30) that  skin grafts  performed in humans 
where there was HLA antigen identity, but mixed lymphocyte response noni- 
dentity,  survived  longer  (22  vs.  11.7 days)  in  preimmunized hosts  than  in 
nonimmunized recipients, suggesting that non-HLA antibodies can play a role 
in human graft enhancement. 
In the light  of these findings it  may be possible to  explain the previously 
mentioned report showing lack of strain specificity of enhancing alloantisera 
(14).  DA anti-Lew serum enhanced AS2 kidneys transplanted into DA hosts; 
however, the antiserum was not cytotoxic for ASz lymphocytes. AS2 and Lew 
rats differ at the Ag-B locus, but share some antigenic specificity as shown by 
cross-absorption studies. It is possible that the shared specificities are, in light of 
the present data,/-region antigens. 
Current knowledge about the mechanism of enhancement is far from com- 
plete (1); however, several observations, including those presented in this paper, 
suggest  a  tenable  hypothesis.  Firstly,  Ia  antigens  are  present on passenger 
leukocytes (31, 32) and possibly on endothelium of the graft. Secondly, the most 
important functional alteration of the enhanced host appears to be abrogation of 
its capacity to produce IgG-mediated lesions in the graft (6, 7), rather than the 
comparatively minor alterations of cell-mediated immunity (6, 33). This altera- 
tion of the humoral immune response of the host closely mimics the impaired 
IgG response seen when T-B collaboration is lacking during the induction phase 
of immunity (34). Thirdly, both the studies presented here and those previously 
mentioned in the mouse (12) suggest that antibodies directed against Ia antigens 
are  enhancing.  Fourthly,  allogeneic effect factor  (AEF),  prepared  from  the 
supernate  of mouse  lymphocyte cultures,  is  able  to  boost  the  in  vitro  IgG 
response of allogeneic cells to antigen.  This allogeneic effect is abrogated by 
passing the AEF-containing supernate through an anti-Ia  immunoabsorbent 
column, suggesting identity between AEF and Ia (35). SOULILLOU, CARPENTER, d~APICE~ AND STROM  419 
It is therefore hypothesized that  enhancing  antiserum  acts by virtue of its 
content of specific anti-"Fc receptor" (Ia) antibodies,  which bind to Ia antigens 
present in, or coming from, the allograft and impair the allogeneic effect which 
normally  results  from  graft-host  contact  and  so decreases  the  IgG  response 
which  is  of prime  importance  in  the  rejection  reaction.  This  hypothesis  is 
consistent  with the available  data concerning the mechanism of  passive  en- 
hancement (1) and could explain  how an antiserum directed  against  target 
antigens  can  affect  the  host  immune response,  thus unifying  the  old  central  and 
peripheral  blockade theories  regarding the mechanism of  action  of  enhancing 
sera,  neither  of  which  alone  have  provided  adequate  explanation  for  the  phenom- 
enon. 
Summary 
The ability of a hyperimmune Lew anti-BN serum (HIS) to induce enhance- 
ment of (Lew/BN)F1 kidneys transplanted  into Lew recipients was compared to 
that of the same antiserum that had been depleted of hemagglutinating anti-Ag- 
B antibodies by absorption with Brown-Norway (BN) RBC-absorbed sera (RAS) 
or platelet-absorbed  sera  (PAS).  The  RAS  and  PAS  were as effective as the 
unabsorbed HIS in abrogating early rejection as assessed by renal function and 
promotion of long-term  survival.  The  absorbed sera retained  the  capacity to 
block the mixed lymphocyte culture (MLC) between Lew and BN lymphocytes 
and to a  lesser degree the MLC between Lew and BUF,  WF, AUG,  and ACI 
lymphocytes; however, strain specificity was clearly evident at high antiserum 
dilutions.  Similarly,  the~e absorbed sera retained the capacity to block the Fc 
receptor of BN lymphocytes, and this effect was completely strain  specific. In 
contrast, hemagglutinating  and cytotoxic antibodies eluted from platelets used 
for antiserum  absorption did not react with Fc receptors as assessed by rabbit 
antisheep (IgG)-coated SRBC (EA) rosette formation. F(Ab')~ fragments of PAS 
also blocked EA rosettes. On the other hand,  complement rosettes (EAC) were 
not inhibited by the HIS. The antibodies were therefore directed against the Fc 
receptor itself or a structure spatially or functionally closely related to it. Both 
the Fc receptors and the enhancing capacity of the antisera were strictly specific 
for the BN genotype. It is suggested that the anti-"Fc receptor" antibody could 
play an important role in the induction of enhancement by impairing host T-B 
collaboration as a result of its binding to graft allogeneic "Fc receptors" which 
appear to be analogous to the major histocompatibility complex (MHC)-coded Ia 
antigens of the mouse. 
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